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http://dx.doi.org/10.1016/j.ccr.2014.02.019SUMMARYColorectal cancer is frequently associated with chronic inflammation, with the intestinal epithelial barrier
playing an important protective role against the infections and injuries that cause colitis. The p38a pathway
regulates inflammatory responses but can also suppress tumor initiation in epithelial cells. We have found
that p38a signaling has a dual function in colorectal tumorigenesis. On one side, p38a protects intestinal
epithelial cells against colitis-associated colon cancer by regulating intestinal epithelial barrier function.
Accordingly, p38a downregulation results in enhanced colitis-induced epithelial damage and inflammation,
which potentiates colon tumor formation. Surprisingly, inhibition of p38a in transformed colon epithelial cells
reduces tumor burden. Thus, p38a suppresses inflammation-associated epithelial damage and tumorigen-
esis but contributes to the proliferation and survival of tumor cells.INTRODUCTION
Cancer is a complex disease that arises through a multistep,
mutagenic process. Acquisition of cancer cell features involves
changes in the wiring of signaling pathways that are normally
tightly regulated to control processes such as cell proliferation,
survival, and differentiation, which are critical to maintain tissue
homeostasis.
Colorectal tumors are of epithelial origin and develop from
sequential mutations in the Wnt signaling pathway, K-Ras,
p53, and the transforming growth factor (TGF)-b pathway
(Fearon and Vogelstein, 1990; Ullman and Itzkowitz, 2011).
Most of these mutations are induced by environmental factors,
such as chronic inflammation of the colon epithelia. It is well es-
tablished that chronic inflammation may lead to increased risk
of several types of cancer (Mantovani et al., 2008; SchetterSignificance
Inflammatory bowel disease (IBD) patients have higher risk
signaling pathways involved in the pathogenesis of IBD is lim
cells is required to maintain epithelial barrier function and inte
p38a negatively regulates the formation of colitis-associated co
cells rely on p38a signaling for survival and proliferation. The re
lation or pharmacological inhibition of p38a suggests therap
pathway.
484 Cancer Cell 25, 484–500, April 14, 2014 ª2014 Elsevier Inc.et al., 2010). For example, patients with inflammatory bowel dis-
ease (IBD), such as Crohn’s disease and ulcerative colitis, have
higher risk of colorectal cancer development than the healthy
population (Gillen et al., 1994). The intestinal epithelial barrier
plays an important role protecting the gastrointestinal tract.
This barrier consists of a mucus layer, which acts as a physical
barrier, and the epithelial layer firmly adhered with epithelial
tight junctions (Rescigno, 2011). Defects in the barrier function
allow direct contact of intestinal mucosa with the luminal
invading pathogens and ingested toxins promoting inflamma-
tory responses. IBD and colon cancer have been associated
with abnormal epithelial barrier function (Schmitz et al., 1999;
Westbrook et al., 2010; Grivennikov et al., 2012). Moreover,
mouse models with defects in epithelial barrier have increased
susceptibility to colitis and colorectal tumor formation, providing
evidence for the regulation of inflammation and tumorigenesisof colorectal cancer development, but the knowledge of
ited. In this study, we show that p38a signaling in epithelial
stinal homeostasis, controlling the severity of colitis. Thus,
lon tumors. It is striking that transformed intestinal epithelial
duced colon tumor burden observed on genetic downregu-
eutic opportunities for colorectal cancer by targeting this
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Van der Sluis et al., 2006).
p38a is a mitogen-activated protein kinase (MAPK) that
regulates the cellular responses to stress but also has other
functions, including crucial roles in inflammation and tissue
homeostasis (Cuenda andRousseau, 2007). Genetic inactivation
of p38a in myeloid cells supports the importance of this pathway
in cytokine production and inflammatory responses (Kang et al.,
2008; Kim et al., 2008a). There is also evidence that p38a
signaling controls tissue homeostasis by inducing differentiation
while negatively regulating proliferation of many cell types,
including epithelial cells (Cuadrado and Nebreda, 2010). It is
interesting that p38a-deficient mice are more susceptible to
K-Ras-induced lung tumorigenesis and to diethylnitrosamine
(DEN)/phenobarbital (Pb)-induced liver cancer, indicating that
p38a can function as a tumor suppressor in vivo (Hui et al.,
2007; Ventura et al., 2007). However, there is little evidence for
p38a inactivating mutations in tumors, which probably reflects
that cancer cells take advantage of the ability of this signaling
pathway to control multiple cellular processes. In line with this
idea, chemical inhibitors of p38a have been shown to impair
the proliferation of some human cancer cell lines (Wagner and
Nebreda, 2009).
Given the role of the p38a pathway in orchestrating inflamma-
tory responses while negatively regulating epithelial cell transfor-
mation, we investigated how these two functions are balanced
in colon epithelia during colitis-associated colorectal cancer
(CAC).
RESULTS
Downregulation of p38a in Intestinal Epithelial Cells
Increases CAC
We generated mice expressing Villin-Cre and p38a-lox alleles to
downregulate p38a in intestinal epithelial cells (IEC) (p38a-DIEC).
The efficiency of p38a downregulation was confirmed by west-
ern blotting in isolated IEC and inwhole-colon lysates (Figure 1A).
To investigate the role of p38a in CAC, we used a protocol that
combines the carcinogen azoxymethane (AOM) with dextran so-
dium sulfate (DSS)-induced colitis (Figure 1B). When we applied
the AOM/DSS protocol, p38a-DIEC mice and wild-type (WT) lit-
termates developed colon tumors mainly in the distal to middle
colon (Figure 1C), which is the predominant localization of
human colorectal tumors. We noticed that p38a-DIEC mice had
more macroscopic tumors (Figure 1D; Figure S1A available
online), and the average tumor load was also higher but the
average size was not affected (Figure 1D). Histological analyses
confirmed more low-grade and high-grade tumors in p38a-DIEC
mice, but the relative proportion of low- versus high-grade
tumors was similar in p38a-DIEC and WT mice (Figure 1E). We
also analyzed cell proliferation and apoptosis in these tumors
and found no significant differences between WT and p38a-DIEC
mice (Figures 1F and S1B).
Inflammatory mediators are upregulated during AOM/DSS-
induced colon tumorigenesis. We found that AOM/DSS-treated
p38a-DIEC mice showed higher COX-2 and interleukin (IL)-6
mRNA levels in the colon than the treated WT mice (Figure S1C).
It is interesting that circulating IL-6 levels were also higher in
serum from p38a-DIEC mice at the end of the AOM/DSS protocol(Figure S1D). This is consistent with the known importance of
IL-6 in colon tumor development.
Analysis of genomic DNA by quantitative PCR (qPCR) showed
a substantial deletion of the floxed exon 2 of p38a in EpCAM+ tu-
mor epithelial cells, but not in CD45+ leukocytes, from p38a-DIEC
mice versus WT mice (Figure 1G). Western blot analysis
confirmed the downregulation of p38a protein in colon tumors
from p38a-DIEC mice (Figure S1E). The increased tumor burden
observed in p38a-DIEC mice without apparent effect on tumor
size suggests that epithelial p38a signaling suppresses CAC
by regulating tumor initiation.
p38a-DIEC Mice Are More Susceptible to DSS-Induced
Colitis and Epithelial Damage
AOM is a potent DNA damage-inducing agent that induces rapid
p53-dependent apoptosis of IEC at the crypt base (Toft et al.,
1999). However, AOM-induced DNA damage and apoptosis
were similar in the colon from WT and p38a-DIEC mice (Figures
S2A and S2B), suggesting that the differences in tumorigenesis
between WT and p38a-DIEC mice were not due to a different
initial response of IEC to AOM.
Next, we investigated the role of p38a in DSS-induced acute
colitis, which is critical for AOM/DSS-induced tumorigenesis. Af-
ter 5 days of DSS administration, p38a-DIEC mice lost more body
weight thanWTmice (Figure 2A) suggesting that p38a-DIEC mice
probably had enhanced inflammation and intestinal damage, as
body weight loss is one of the indicators for the severity of DSS-
induced colitis. To confirm this possibility, mice were given DSS
for 5 days and analyzed 1 or 3 days later. At both days 6 and 9,
the WT colon showed minimal to mild inflammation, while colon
from p38a-DIEC mice showed moderate to severe inflammation,
with many areas of complete crypt loss and erosions (Figure 2B).
We also noticed that DSS-treated p38a-DIEC mice had signifi-
cantly more epithelial damage in the distal-middle part of the
colon (Figure 2C).
Increased Inflammatory Cell Infiltration in p38a-DIEC
Mice Treated with DSS
Since p38a-DIEC mice showed higher epithelial damage and
inflammation, we characterized immune cell infiltration in the
colon from DSS-treated mice. At day 6, we found a higher num-
ber of infiltrating cells in the colon of p38a-DIEC mice than in WT
mice (Figure 2D). Flow cytometry analyses showed more leuko-
cytes (CD45+ cells) in both epithelial/intraepithelial and lamina
propria fractions of p38a-DIEC mice. B cells (CD45+CD19+)
also accumulated more in the lamina propria of p38a-DIEC
mice, whereas neutrophil (CD45+CD11b+Gr1+) infiltration was
very similar in the colons of WT and p38a-DIEC mice (Fig-
ure S2C). We also found more macrophages in the colon of
DSS-treated p38a-DIEC mice compared to WT mice, whereas
untreated mice showed no differences in macrophage infiltra-
tion (Figure S2D).
Infiltrating immune cells produce cytokines and chemokines to
resolve the inflammation process. We found that IL-6 and COX-2
mRNAs were both upregulated in the colon from DSS-treated
p38a-DIECmice compared toWTmice, whereas IL-1a and tumor
necrosis factor a (TNF-a) mRNAs did not change. Basal expres-
sion levels of these mRNAs were comparable in untreated WT
and p38a-DIEC mice (Figure 2E). We also found higher IL-6Cancer Cell 25, 484–500, April 14, 2014 ª2014 Elsevier Inc. 485
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Figure 1. Downregulation of p38a in IEC Increases Susceptibility to AOM/DSS-Induced Colon Tumorigenesis
(A) Western blotting of p38a in whole-colon lysates (colon) and in isolated IEC (crypts).
(B) Schematic representation of the AOM/DSS protocol. i.p., intraperitoneal.
(C) Representative images of colon tumors.
(D) Average tumor number, size, and load. Data represent means ± SEM (nR 6). *p < 0.05.
(E) Representative images of H&E-stained colon tumors at the end of the AOM/DSS protocol. Scale bars, 50 mm. Tumors were microscopically analyzed and
classified into low or high grade (n = 8).
(F) Colon sections were stained for bromodeoxyuridine (BrdU) or cleaved caspase 3 and quantified. Data represent means ± SEM (n = 4).
(G) Relative amount of the floxed exon 2 of p38a versus exon 12 (as a control) was determined by qPCR in EpCAM+ epithelial cells andCD45+ leukocytes. Data are
means ± SEM (nR 11). *p < 0.05.
See also Figure S1.
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treated p38a-DIEC mice (Figure 2F). The increased IL-6 levels
observed in p38a-DIEC mice were unexpected, since the p38a
pathway is known to positively regulate IL-6 expression in
several cell types (Cuenda and Rousseau, 2007). Expression
analysis using flow-cytometry-isolated cells showed that IL-6,
IL-1a, and COX-2 mRNAs were all upregulated in IEC from
DSS-treated p38a-DIEC mice compared to WT mice, whereas
TNF-a mRNA levels did not change. In contrast, the aforemen-
tioned inflammatory mediators were expressed at similar levels
in the leukocytes from colon of WT or p38a-DIEC mice (Fig-
ure S2E), which is consistent with the leukocytes being WT in
both cases. Thus, the upregulation of IL-6 and COX-2 can be
probably explained by both the presence of more infiltrating
immune cells in colon of p38a-DIEC mice and the enhanced
expression of these cytokines in p38a-deficient IEC. Consistent
with the increased IL-6 expression observed in DSS-treated
p38a-DIEC mice, we also detected phosphorylation and degra-
dation of IkBa, suggesting activation of the NF-kB pathway, as
well as enhanced phosphorylation of STAT3, a downstream
target of IL-6 family receptors (Figure 2G).
Loss of p38a in IEC Induces Apoptosis and
Hyperproliferation on DSS Treatment
Epithelial apoptosis is one of the mechanisms by which DSS
can induce intestinal inflammation and colitis. We found that
treatment with DSS induced more apoptosis in p38a-DIEC
mice than in WT mice (Figure 3A). Western blotting of IEC iso-
lated from WT mice confirmed that DSS treatment increased
the activating phosphorylation of p38a (Figure 3B). Analysis of
Bcl-2 family members revealed that the proapoptotic protein
Bak was significantly upregulated in DSS-treated p38a-DIEC
mice, whereas Bax and the antiapoptotic proteins Mcl-1, Bcl-
2, and Bcl-XL were expressed at similar levels in DSS-treated
WT and p38a-DIEC mice (Figure 3B). In contrast, p53 expres-
sion and JNK phosphorylation levels were not changed (Fig-
ure 3B), suggesting that these pathways do not contribute to
the enhanced apoptosis observed in DSS-treated p38a-DIEC
mice. Therefore, increased apoptosis, probably mediated by
upregulation of Bak, could explain the increased epithelial dam-
age and inflammation observed in the p38a-DIEC mice on DSS
treatment.
In response to the DSS-induced damage, the intestinal
epithelium starts the repair and regeneration process by
increasing cell proliferation. Since we detected more IL-6, an
important regulator of the proliferation and survival of IEC
(Bollrath et al., 2009; Grivennikov et al., 2009), we analyzed
cell proliferation in the colon from DSS-treated mice. At day 6,
we observed similar cell proliferation levels in intact crypts of
WT and p38a-DIEC mice; however, p38a-DIEC mice had more
proliferative cells than WT mice had in the areas of complete
crypt loss, which probably represents a mixture of IEC and
inflammatory cells (Figure 3C). At days 9 and 13, we found
higher proliferation rates in IEC from WT and p38a-DIEC mice
compared to untreated mice. It is surprising that IEC prolifera-
tion was much higher in p38a-DIEC than in WT mice during
epithelium regeneration (Figure 3C). These data suggest that
p38a downregulation results in IEC hyperproliferation after
DSS-induced epithelial damage.DSS Treatment Suffices to Induce Colon Tumors in
p38a-DIEC Mice
Unchecked compensatory proliferation and regeneration
induced in response to repetitive tissue injury can promote
tumorigenesis (Kuraishy et al., 2011). To test this possibility,
we treated mice with three cycles of DSS but in the absence of
the AOM carcinogen (Figure 4A). Macroscopic examination re-
vealed thatWTmice did not develop any tumors; however, about
60% of the p38a-DIEC mice developed at least one colon tumor
(Figure 4A). Histological examination confirmed the presence
of colon tumors in p38a-DIEC mice, which also contained more
aberrant crypt foci with hyperchromatism of nuclei and hyper-
plastic crypts compared to WT mice (Figure 4B). The tumors
formed in p38a-DIEC mice had mutated b-catenin, correspond-
ing to a GSK3b phosphorylation site, which leads to b-catenin
activation and nuclear localization (Figures S3A and S3B). In
addition, there weremoremacrophages in colon from p38a-DIEC
mice than from WT mice (Figure 4C). The inflammatory media-
tors COX-2, IL-6, TNF-a, and IL-12p40 were also expressed at
higher levels in the colon from p38a-DIEC mice than from WT
mice (Figure 4D). Taking together, these data suggest that
repeated DSS-induced epithelial injury in the absence of p38a
results in uncontrolled hyperproliferation of IEC and a protumori-
genic microenvironment that ultimately can induce colon hyper-
plasia and tumor formation.
p38a Regulates Homeostasis and Barrier Function in
Normal Intestinal Epithelium
Alterations in epithelial barrier function have been associated
with IBD and colon cancer (Grivennikov et al., 2012; Westbrook
et al., 2010). We hypothesized that the increased epithelial dam-
age and inflammation observed on p38a downregulation could
be due to altered intestinal homeostasis and barrier function.
In agreement with a recent report (Otsuka et al., 2010), we
found that p38a downregulation in IEC had no effect on colon
morphology, although p38a-DIEC mice had more proliferative
colon cells than the WT littermates. We also analyzed two main
types of differentiated colon cells and found fewer chromogranin
A+ (ChgA) enteroendocrine cells and periodic acid-Schiff + (PAS)
goblet cells in p38a-DIEC mice compared to WT mice (Figure 5A;
Figure S4A). Expression analysis confirmed upregulation of
genes encoding proteins associated with cell proliferation (Ki67
and cyclin D1) and downregulation of differentiation-related
genes (MUC-2, TFF3, andChgA) in p38a-DIEC mice (Figure S4B).
These results indicate that p38a signaling can modulate both
proliferation and differentiation of IEC.
Epithelial tight junctions are intercellular junctional complexes
that regulate the paracellular permeability and are important for
integrity of the epithelial barrier. Each tight junction contains
a series of apparent fusions, called kissing points, where the
intercellular space is completely obliterated (Tsukita et al.,
2001). To investigate the epithelial barrier function, we first
analyzed the effect of p38a downregulation on intestinal perme-
ability. Using fluorescein isothiocyanate (FITC)-dextran, we
found that in vivo intestinal permeability was notably increased
in p38a-DIEC mice (Figure 5B). Electron microscopy analysis re-
vealed that epithelial tight junctions in colon fromp38a-DIECmice
were morphologically disrupted and had fewer kissing points
compared to WT mice (Figures 5C and S4C). ZO-1 is a keyCancer Cell 25, 484–500, April 14, 2014 ª2014 Elsevier Inc. 487
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claudins and occludin to assemble at a tight junction (McNeil
et al., 2006). Expression of ZO-1 was reduced in p38a-DIEC
mice, while claudin-1 and occludin seemed to be expressed at
similar levels in WT and p38a-DIEC mice (Figures 5D and S4D).
These results suggest a role for p38a in the regulation of intesti-
nal epithelia tight junction assembly and barrier function. In
agreement with a recent study (Grivennikov et al., 2012), we
also found upregulation of IL-23 mRNA in colon tumors versus
normal tissue, but no differences were detected between WT
and p38a-DIEC mice. Similarly, IL-17 mRNA was expressed at
similar levels in WT and p38a-DIEC mice (Figure S4E). Thus, the
epithelial barrier defect observed in p38a-DIEC mice does not
seem to be associated with IL-23 and IL-17 upregulation, but it
is probably a consequence of the regulation by p38a of epithelial
tight junction assembly.
To investigate whether intestinal barrier defects have a causal
role in the enhanced epithelial damage induced by DSS in
p38a-DIEC mice, we used the probiotic mixture VSL#3 to protect
the epithelial barrier (Mennigen et al., 2009). It is interesting that
VSL#3 treatment for 7 days rescued the increased intestinal
permeability observed in p38a-DIEC mice (Figure 5E). Moreover,
VSL#3 also rescued the enhanced apoptosis, the body weight
loss, and the epithelial damage induced by DSS in p38a-DIEC
mice (Figures 5F–5H). These results support that the impaired
epithelial barrier function contributes to the DSS-induced pheno-
types of p38a-DIEC mice, and it seems therefore likely that the
epithelial barrier defect also contributes to the enhanced CAC
observed in p38a-DIEC mice.
Downregulation of p38a in Tumor Epithelial Cells
Reduces Tumor Burden
Chemical inhibitors of p38a have been reported to inhibit prolif-
eration in some cancer cells, including human colon cancer cell
lines (Wagner and Nebreda, 2009). However, our genetic
analysis indicated that p38a suppressed colon tumor formation.
To clarify the role of p38a in colon tumorigenesis, we generated
a mouse line with Villin-CreERT2 and p38a-lox alleles
(p38a-DIEC-ERT2). We confirmed that treatment with 4-hydroxy
tamoxifen (4-OHT) induced p38a downregulation in colon but
not in other tissues of p38a-DIEC-ERT2 mice (Figure S5A). Next,
we verified our results using constitutive Villin-Cre by inducing
p38a downregulation before DSS or AOM/DSS treatments (Fig-
ure S5B). We found that 4-OHT-treated p38a-DIEC-ERT2 mice
developed more tumors than WT mice, but of similar size (Fig-
ure S5C). Moreover, after DSS treatment, p38a-DIEC-ERT2 mice
lost more body weight thanWTmice, as in the case of p38a-DIEC
mice (Figure S5D).Figure 2. Downregulation of p38a in IEC Increases Susceptibility to DS
(A) DSS was administered in drinking water for 5 days, and body weight was rec
(B) Representative H&E-stained colon sections from mice either untreated or tre
(C and D) Quantification of DSS-induced epithelial damage (C) and immune cell infi
*p < 0.05.
(E) Relative mRNA expression levels of inflammatory mediators in the distal colo
transcription PCR (qRT-PCR). Expression levels in untreatedWT and p38a-DIEC m
*p < 0.05.
(F) IL-6 protein levels in blood serum and whole-colon lysates of DSS-treated m
(G) Colon lysates were prepared from DSS-treated mice and were analyzed by w
See also Figure S2.We next investigated the effect of p38a downregulation once
colon tumors were formed. First, mice were subjected to the
AOM/DSS protocol, and the presence of colon tumors was
confirmed 65 days after the AOM injection. Then, mice with
p38a-lox, and either with or without Villin-CreERT2, were in-
jected with 4-OHT (Figure 6A). Three days after 4-OHT injection,
p38a downregulation was poor, and no differences were de-
tected in tumor number and size (Figure S5E). The downregula-
tion of p38a improved at 10 days after 4-OHT injection when
both tumor number and size started to decrease (Figure S5F).
It is interesting that, 20 days after the last 4-OHT injection,
tumors from p38a-DIEC-ERT2 mice were mostly p38a deficient,
as determined by western blotting (Figure 6B), by immunohisto-
chemistry (IHC) (Figure S5G), and by analyzing the deletion of
the floxed exon 2 of p38a in genomic DNA (Figures S5H and
S5I). At this time, we observed that the average number, size,
and load of macroscopic tumors were significantly reduced
in p38a-DIEC-ERT2 mice compared with WT mice (Figure 6C and
6D). Of note, tumor burden and average tumor size both
increased in WT mice compared to those of the initial tumors,
suggesting that tumors continue to grow after 4-OHT injection
(Figure 6D). When tumor size distribution was analyzed, we
found fewer big colon tumors on p38a downregulation in tumor
epithelial cells (Figure 6D). However, histological analysis re-
vealed no differences in tumors from WT or p38a-DIEC-ERT2
mice (Figure 6E). These results indicate a protumorigenic role
for p38a in transformed colon epithelia cells.
Downregulation of p38a in Tumor Epithelial Cells Does
Not Affect Tumor Permeability and Invasiveness
Recent studies described the importance of epithelial barrier
function in colorectal tumors and invasiveness (Grivennikov
et al., 2012; Schwitalla et al., 2013). We therefore investigated
if the downregulation of p38a could result in more aggressive
colon tumors. To test this hypothesis, p38a-DIEC-ERT2 mice
were analyzed 45 days after 4-OHT injections. Initial experiments
showed no differences in tumor burden or grading (Figures S6A
and S6B), but western blotting revealed significant amounts of
p38a in these tumors, probably corresponding to p38a-express-
ing escaper cells that repopulated the tumors in p38a-DIEC-ERT2
mice (Figure S6C). To circumvent this problem, we performed
two rounds of 4-OHT injections (Figure S6D). In this case, we
confirmed the sustained downregulation of p38a in the tumors
(Figure S6E), which correlated with reduced tumor number and
size in p38a-DIEC-ERT2 mice (Figure S6F). However, no differ-
ences were detected in histological tumor grading or aggres-
siveness between p38a-DIEC-ERT2 and WT mice (Figure S6G),
suggesting that constant inhibition of p38a signaling is requiredS-Induced Colitis and Immune Cell Infiltration
orded. Data are means ± SEM (nR 8). *p < 0.05.
ated with DSS for 5 days and analyzed at days 6 and 9. Scale bars, 100 mm.
ltration (D) in H&E-stained colon sections. Data represent means ± SEM (n = 4).
n of untreated and DSS-treated mice were determined by quantitative reverse
ice were the same andwere given the value of 1. Data are means ± SEM (n = 4).
ice. Data are means ± SEM (n = 5).
estern blotting (one mouse per lane) with the indicated antibodies.
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Figure 3. Downregulation of p38a in IEC Results in Enhanced DSS-Induced Apoptosis and Compensatory Proliferation
(A) Representative TUNEL staining of colon sections after 3 days of treatment with 3% DSS. Quantification is shown in the histogram. Data represent means ±
SEM (n = 3). *p < 0.05.
(legend continued on next page)
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Figure 4. DSS Alone Suffices to Induce Colon Tumors in p38a-DIEC Mice
(A) Schematic representation of the DSS protocol used to induce chronic colitis (top) and the summarized results (bottom).
(B) Representative images of H&E-stained colon sections at the end of the DSS treatment.
(C) Colon sections from mice treated with three cycles of DSS were stained for F4/80 to detect macrophages.
(D) Relative mRNA expression levels of the indicated genes in mouse colons were determined by qRT-PCR. Data are means ± SEM (n = 4). *p < 0.05.
Scale bars, 50 mm.
See also Figure S3.
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effect on tumor aggressiveness.
Next, we measured intestinal permeability and found that,
similar to p38a-DIEC mice, permeability was higher in untreated
p38a-DIEC-ERT2 mice than in WT mice, but we could detect no dif-
ferences in tumor permeability between WT and p38a-DIEC-ERT2
mice (Figure S6H; see also Supplemental Experimental Proce-(B) Colon epithelial cells were obtained from untreated or DSS-treated mice, an
indicated antibodies. The histogram shows the quantification of Bak expression
(C) Sections from the distal colon of mice treated with 2% DSS for 5 days were st
intact crypts; the right panels show an area with damage and crypt loss. Panels
Scale bars, 50 mm.dures for tumor permeability calculation). In agreement with the
permeability analysis, we found that p38a downregulation in
colon tumors did not affect expression of the tight junction
components ZO-1, ZO-2, Claudin-1, Occludin, and JAM-C
(Figures S6I and S6J). Taken together, these results indicate
that the reduced tumor burden observed in p38a-DIEC-ERT2
mice is unlikely to be associated with enhanced tumord samples were analyzed by western blotting (one mouse per lane) with the
. Data represent means ± SEM (n = 3). *p < 0.05.
ained for Ki67 at days 6, 9, and 13. For day 6: the left panels show an area with
for days 9 and 13 show regenerating epithelia.
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downregulation.
Downregulation of p38a Reduces Proliferation and
Increases Apoptosis in Colon Tumor Cells
To investigate themolecular basis for the reduced tumorigenesis
in p38a-DIEC-ERT2 mice, we analyzed the levels of cell prolifera-
tion and apoptosis. We found significantly reduced cell prolifer-
ation but increased apoptosis in the tumors from p38a-DIEC-ERT2
mice compared to WT mice (Figure 7A). In agreement with the
known importance of the cytokines IL-6 and IL-11 and the che-
mokines CXCL-1 and CXCL-2 for colon tumorigenesis (Grivenni-
kov et al., 2009; Jamieson et al., 2012; Katoh et al., 2013;
Putoczki et al., 2013), we found that IL-6, IL-11, CXCL-1, and
CXCL-2 were all significantly downregulated in the colon tumors
from p38a-DIEC-ERT2 mice (Figure 7B). Both CXCL-1 and CXCL-2
attract cells expressing the CXCR2 receptor, mostly neutrophils
and myeloid-derived suppressor cells that are positive for mye-
loperoxidase (MPO) staining and contribute to inflammation-
driven tumorigenesis (Jamieson et al., 2012; Katoh et al.,
2013). Reduced expression of CXCL-1 and CXCL-2 correlated
with fewer MPO+ cells in p38a-deficient tumors (Figure S6K).
However, macrophage infiltration was not affected by downre-
gulation of p38a in tumor cells (Figure 7C). We also found that
p38a downregulation in colon tumors resulted in enhanced
levels of phosphorylated JNK and reduced levels of phosphory-
lated STAT3, whereas the prosurvival pathways ERK1/2 and Akt
were not affected (Figure 7D). Moreover, expression of the anti-
apoptotic protein Mcl-1 was reduced in the p38a downregulated
colon tumors, which may contribute to the enhanced apoptosis
observed in p38a-DIEC-ERT2 mice (Figure 7E). These results
support an important role for p38a in colon tumor maintenance
by promoting proliferation and inhibiting apoptosis of the tumor
cells.
Chemical Inhibition of p38a Reduces Colon Tumor
Burden in Mice
The aforementioned findings were confirmed using PH797804,
a chemical compound that potently inhibits p38a and is being
used in clinical trials for inflammatory diseases (Goldstein
et al., 2010). Colon tumors were induced using the AOM/DSS
protocol, and then mice were separated in two groups that
received either PH797804 or vehicle for 12 days (Figure 8A).
We found that mice treated with the p38a inhibitor had a signif-
icantly reduced colon tumor load, reflecting both fewer tumorsFigure 5. Downregulation of p38a in IEC Affects Intestinal Homeostas
(A) Quantification of proliferating Ki67+ cells, PAS+ goblet cells, and ChgA+ enter
(B) Intestinal permeability was measured by determining the concentration of FIT
(C) Representative electronmicroscope images showing tight junctions in colon e
shows the quantification of the number of kissing points per tight junction. Data
(D) Colon lysates were analyzed by western blotting (one mouse per lane) with th
(E) Mice were treated with PBS or probiotic mixture VSL#3 for 1 week, and inte
*p < 0.05.
(F) Mice were treated as in (E) and then with 3% DSS for 3 days. TUNEL+ apopto
(G) Mice were treated as in (E) and then with 2% DSS for 5 days. Body weights we
SEM (nR 4). *p < 0.05.
(H) Mice were treated as in (G) and killed at day 6. Colon sections were stained w
quantification of the epithelial damage. Data are means ± SEM (nR 3). *p < 0.05
See also Figure S4.and smaller sizes compared to vehicle-treated mice (Figure 8B).
IHC analysis confirmed the inhibition of colon tumorigenesis
by administration of PH797804, which also reduced p38 MAPK
signaling in the colon tumors and in adjacent normal epithelia
(Figures 8C and 8D). These results extend our genetic analysis,
indicating a protumorigenic role for p38a signaling in colon tumor
cells. Moreover, incubation of Caco-2 and SW-620 human colon
cancer cell lines with three different p38 MAPK chemical inhibi-
tors resulted in enhanced apoptosis (Figure 8E), which corre-
lated with increased levels of phosphorylated JNK (Figure 8E),
as observed on p38a downregulation in mouse colon tumors.
Collectively, our results indicate that p38a signaling plays a
dual role during colorectal tumorigenesis, suppressing the initial
stages that lead to IEC transformation but contributing to tumor
maintenance (Figure 8F).
DISCUSSION
In this study, we show that p38a suppresses colitis-associated
colon tumor initiation by regulating the epithelial barrier function,
which protects against epithelial damage and inflammation.
However, once colon tumors are formed, p38a facilitates tumor-
igenesis by promoting proliferation and inhibiting apoptosis of
the transformed epithelial cells.
In agreement with previous evidence for the tumor suppressor
role of p38a in mouse models of lung and liver cancer (Hui et al.,
2007; Ventura et al., 2007), we show that p38a downregulation
in IEC enhances CAC. The AOM/DSS protocol is highly depen-
dent on DSS, which induces epithelial apoptosis and inflamma-
tion. For example, downregulation of NEMO (NF-kB essential
modulator) or STAT3 in IEC results in chronic colitis due to exces-
sive IEC apoptosis (Bollrath et al., 2009; Nenci et al., 2007).
Similarly, we show that p38a-deficient IEC undergo extensive
apoptosis onDSS exposure, which correlateswith the accumula-
tion of the proapoptotic protein Bak. It has been proposed, in a
different context, that negative regulation of Bak expression
by p38a attenuates ionizing radiation-induced cell death (Kim
et al., 2008b). The increased apoptosis observed in DSS-treated
p38a-DIEC mice extends a recent report showing more epithelial
damage in p38a-deficient than in WT mice treated with DSS
(Otsuka et al., 2010). In addition, we have found enhanced DSS-
induced inflammatory cell infiltration in p38a-DIEC mice. Different
DSS treatment conditions might account for the discrepancies.
DSS-treated p38a-DIEC mice produce increased levels of IL-6,
a critical cytokine for colorectal tumorigenesis that regulates IECis and Paracellular Permeability
oendocrine cells. Data are means ± SEM (n = 4). *p < 0.05.
C-dextran in blood serum. Data are means ± SEM (n = 4). *p < 0.05.
pithelia. Scale bars, 50 nm. At least 25 tight junctions were analyzed. Histogram
are means ± SEM. *p < 0.05.
e indicated antibodies.
stinal permeability was determined as in (B). Data are means ± SEM (n R 3).
tic cells were quantified. Data are means ± SEM (n = 3). *p < 0.05.
re recorded before starting the DSS treatment and at day 6. Data are means ±
ith H&E and histologically analyzed. Scale bars, 50 mm. The histogram shows
.
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Figure 6. Downregulation of p38a in Colon Tumor Cells Reduces Tumor Burden
(A) Schematic representation of the protocol used to downregulate p38a in AOM/DSS-induced colon tumors.
(B) Colon tumorswere analyzed bywestern blotting (onemouse per lane). Quantification is shown in the right panel. Data representmeans ±SEM (n = 6). *p < 0.05.
(C) Representative images of colon tumors.
(D) Average tumor number, size, load, and tumor size distribution in initial tumors (day 65) and 20 days after the last 4-OHT injection (day 90). Data represent
means ± SEM (n = 4 for initial tumors and n = 8 for WT and p38a-DIEC-ERT2). *p < 0.05.
(E) Colon tumor sections were stained with H&E and classified into low or high grade based on histological analysis (n = 8).
See also Figure S5.
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Figure 7. Downregulation of p38a Reduces Proliferation and Increases Apoptosis in Colon Tumor Cells
(A) Colon tumor sections were stained with the indicated antibodies. Scale bars, 50 mm. Quantifications are shown in the right panels. Data represent means ±
SEM (n = 8). *p < 0.05.
(B) Relative mRNA expression levels for the indicated genes were determined by qRT-PCR. Data are means ± SEM (n = 4). *p < 0.05.
(legend continued on next page)
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relay on the activation of the transcription factor STAT3 (Becker
et al., 2004; Bollrath et al., 2009; Grivennikov et al., 2009). Sus-
tained activation of the NF-kB pathway also contributes to tumor
development by inducing expression of inflammatory mediators
and growth factors (Greten et al., 2004). Consistent with these
results, the STAT3 and NF-kB pathways are both upregulated
in p38a-DIEC mice after DSS-induced colitis. Enhanced damage
and the inflammation-associated release of cytokines probably
contribute to the hyperproliferation of IEC in p38a-DIEC mice on
repetitive DSS-induced epithelial injury.
Our results demonstrate the importance of p38a signaling in
intestinal homeostasis and integrity of the colon epithelia. Of
particular importance is the reduced number of mucus-produc-
ing goblet cells, which we and others (Otsuka et al., 2010) have
observed in p38a-DIEC mice. Mucins produced by goblet cells
form a protective mucous layer, which serves as a first barrier
to pathogens or chemical injury (Rescigno, 2011). Accordingly,
Muc2 knockout mice spontaneously develop colitis and intesti-
nal tumors, but with a very low incidence (1.5 tumors per mouse
at 1 year of age) (Van der Sluis et al., 2006; Velcich et al., 2002).
However, Muc2+/ mice do not develop spontaneous colitis
but are more sensitive to DSS-induced colitis (Van der Sluis
et al., 2006). Similarly, the decreased expression of MUC2 in
p38a-DIEC mice is not sufficient to induce spontaneous colitis
or tumors but is likely to facilitate DSS-induced colitis and colon
tumor formation as in Muc2+/ mice.
The importance of intestinal epithelial integrity is emphasized
by the altered paracellular permeability and tight junction func-
tions observed in IBD patients (Schmitz et al., 1999; Westbrook
et al., 2010). Moreover, it has been recently reported that colon
tumors have defective epithelial barrier function, which has
been associated with upregulation of IL-23 and IL-17 (Grivenni-
kov et al., 2012). Mice lacking the tight junction protein JAM-A
also show increased intestinal permeability and are more sus-
ceptible toDSS-induced colitis (Laukoetter et al., 2007). Downre-
gulation of p38a in IEC affects epithelial barrier function, which
does not correlate with IL-23 and IL-17 upregulation but with
reduced expression of ZO-1, an important regulator of tight junc-
tion assembly. The probiotic mix VSL#3 can improve defective
barrier function in a model of acute DSS-induced colitis (Menni-
gen et al., 2009). Experiments with VSL#3 support an important
role for p38a in the regulation of intestinal barrier integrity, which
protects against colitis-induced epithelial damage and the initia-
tion of colon tumorigenesis. However, probiotics can alsomodify
the gut microbiota, which might provide further beneficial effects
by restoration ofmicrobial communities andsuppression of path-
ogens and immunomodulation (Preidis and Versalovic, 2009).
In contrast to the in vivo tumor suppressor function of p38a
during the onset of several types of cancer, p38amight facilitate
cancer cell proliferation and survival in established human cell
lines and in some mouse models (reviewed by Wagner and
Nebreda, 2009). These studies are mainly based on the use of
SB203580 and SB202190, two chemical inhibitors that are(C) Colon tumor sections were stained with F4/80 to detect macrophages. Scal
means ± SEM (n = 3).
(D and E) Colon tumor lysates were analyzed by western blotting (one mouse pe
See also Figure S6.
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example, the induction of autophagy by SB202190 in colorectal
cancer cells (Chiacchiera et al., 2009; Comes et al., 2007) has
been ascribed to nonspecific effects rather than to the inhibition
of p38a signaling (Menon et al., 2011). Here, we provide genetic
and pharmacological evidence supporting the implication of
p38a in colon tumor maintenance.
The defective barrier function of colon tumors results in
increased permeability, which contributes to tumorigenesis by
facilitating an enhanced inflammatory response and can also
enable invasiveness by reducing adhesion of tumor epithelial
cells (Grivennikov et al., 2012; Schwitalla et al., 2013). Given
the role of p38a in normal epithelial barrier function, p38a down-
regulation could further enhance tumor permeability, which
should promote tumorigenesis. However, our results show that
p38a does not regulate tumor permeability, which is severely
affected in colon tumors compared with normal intestine. More-
over, the downregulation of p38a reduces tumor burden without
increasing tumor invasiveness, suggesting that p38a is unlikely
to regulate the barrier function in tumors.
Previous studies showed that STAT3 is an important regulator
of colon tumor cell survival and proliferation (Bollrath et al.,
2009; Grivennikov et al., 2009), whose activation is strongly asso-
ciated with expression of IL-6 and IL-11. Inhibition of STAT3, IL-6,
or IL-11 greatly reduces tumorburden in inflammation-associated
colon cancer (Grivennikov et al., 2009; Putoczki et al., 2013). The
p38a pathway can control the production of proinflammatory
cytokines (Cuenda and Rousseau, 2007). We have shown that
expression of IL-6 and IL-11 is reduced in the tumors on p38a
downregulation,which also correlateswith reducedphosphoryla-
tion of STAT3. Autocrine mechanisms, such as the production of
theaforementionedcytokines, couldaccount for theobserved link
between p38a activity and STAT3 phosphorylation, although we
cannot ruleout thatp38amight also regulate intracellular signaling
pathways leading to STAT3 phosphorylation in tumor cells.
Inactivation of p38a in colon tumors induces significant
apoptosis, which correlates with reduced expression of the anti-
apoptotic protein Mcl-1 and increased phosphorylation of JNK.
It is interesting that p38a can negatively regulate JNK signaling
by several mechanisms (Wagner and Nebreda, 2009), and
sustained activation of JNK has been linked to the induction
of apoptosis (Ventura et al., 2006). Moreover, JNK has been
reported to mediate phosphorylation and degradation of Mcl-1
(Morel et al., 2009). Altogether, it seems likely that activation
of JNK signaling together with reduced expression of Mcl-1
contribute to the increased apoptosis observed in colon tumors
on p38a downregulation.
The reappearance of p38a-expressing tumors at 45 days after
4-OHT administration suggests that Villin-CreERT2 induction
does not delete p38a in all transformed epithelial cells and that
the WT escapers eventually repopulate the tumors (Figure 8F).
Thus p38a-deficient tumor cells are at a selective disadvantage
and are outcompeted byWT tumor cells, which is consistent with
the increased apoptosis and reduced proliferation observed ine bars, 100 mm. Quantifications are shown in the right panels. Data represent
r lane) with the indicated antibodies.
A B
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(legend on next page)
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Villin-CreERT2 might not be so effective in cancer intestinal stem
cells. However, Villin-CreERT2 has been shown to be active in all
IEC, including putative progenitor cells in the crypts (el Marjou
et al., 2004), as well as during APC (adenomatous polyposis
coli)-induced polyp formation (Sonoshita et al., 2011). Moreover,
global gene expression analysis has shown that normal intestinal
stem cells are very similar to the cancer stem cells (Merlos-
Sua´rez et al., 2011). It is, therefore, likely that Villin-CreERT2
works in normal intestinal stem cells as well as in all compart-
ments of the intestinal epithelia during cell transformation and
adenoma progression. In any case, it seems that p38a promotes
viability of the majority of colon tumor cells, based on the sub-
stantially impaired colon tumor growth observed on downregula-
tion or inhibition of p38a, and the observation that colon tumors
do not regrow when p38a downregulation is maintained.
Our results also provide an example of a nononcogenic addic-
tive pathway that is important for tumor maintenance (Luo et al.,
2009). The requirement of p38a for colon cancer cell survival and
proliferation does not imply that the pathway should be neces-
sarily upregulated in colon tumor cells. Nevertheless, enhanced
levels of phosphorylated p38 MAPK have been detected in
human colon tumor samples, both in cancer cells and in stromal
cells (Hardwick et al., 2001; Paillas et al., 2011).
In summary, we describe a dual role of p38a signaling in colon
tumorigenesis, suppressing inflammation-associated colon tu-
mor initiation but contributing to tumor maintenance (Figure 8F).
It hasbeen reported that thep38apathwaycanplaydifferent roles
during skin tumorigenesis in epithelial or endothelial cells (Yoshi-
zukaet al., 2012).Our in vivo experiments indicate that p38a func-
tions as tumor suppressor or promoter in normal and transformed
IEC, respectively. It remains to be determined howp38a signaling
in other cell types contributes to colorectal tumorigenesis.
EXPERIMENTAL PROCEDURES
Mice
p38a-DIECmiceandp38a-DIEC-ERT2miceweregeneratedbycrossingp38alox/lox
mice (Ventura et al., 2007) with Villin-Cre and Villin-CreERT2 mice (el Marjou
et al., 2004), respectively. The Villin-Cre mice were mostly in C57BL/6 back-
ground, while Villin-CreERT2 mice were of mixed C57BL/6-129v background.
Littermate controls were used in all experiments. Mice were housed according
to national and European Union regulations, and protocols were approved by
the animal care and use committee of the Barcelona Science Park.
Induction of Colitis and CAC
To induce colorectal tumors, we used a combination of the carcinogen AOM
with repeated administration of DSS in the drinking water, which causes colitis
(Neufert et al., 2007). Mice (8–10weeks old) were injected intraperitoneally with
a single dose of AOM (10 mg/kg; Sigma, #A2853). After 5 days, 2% DSSFigure 8. Chemical Inhibition of p38a Reduces Colon Tumor Burden
(A) Schematic representation of the protocol used to induce colorectal tumors in
(B) Average tumor number, size, and load at the end of the AOM/DSS protocol.
(C) Representative images of colon sections stained with H&E or the phospho-p3
phospho-p38.
(D) Colon lysates were analyzed by western blotting (one mouse per lane) with th
(E) Human colon cancer cell lines were treated with the p38 MAPK inhibitors SB20
and cell lysates were then analyzed by western blotting with the indicated antibo
(F) In normal colon epithelial cells, p38amaintains intestinal homeostasis and bar
p38a contributes to colon tumor development by supporting proliferation and inh
appear to be at a selective disadvantage compared with WT cells.
498 Cancer Cell 25, 484–500, April 14, 2014 ª2014 Elsevier Inc.(molecular weight, 36–50 kDa; MP Biomedicals, #160110) was given in the
drinking water for 5 days, followed by 14 days of regular drinking water. The
DSS treatment was repeated for two additional cycles, and mice were sacri-
ficed 100 days after the AOM injection, except when indicated otherwise.
For short-term colitis and inflammation studies, mice were given 2% DSS for
5 days and sacrificed at the indicated time points. Body weights were
recorded during DSS treatment. Colons were removed from mice, flushed
with cold PBS, opened longitudinally, fixed as ‘‘swiss-rolls’’ in 10% formalin
solution (Sigma, #HT-501128) at room temperature overnight, and paraffin
embedded. Before fixing the colons, size measurements were performed
using a digital caliper in a blinded fashion.
Histopathological Analysis
Paraffin-embedded colon sections were stained with hematoxylin and eosin
(H&E) and analyzed by pathologists in blinded fashion for tumor grades,
epithelial damage, and inflammation using the scoring systems described in
the Supplemental Information.
IHC
For IHC, colon sections were stained with the antibodies indicated in the Sup-
plemental Information. Signals were visualized with 3,3-diaminobenzidine, us-
ing hematoxylin as a counterstain. PAS reagentwas used to detect goblet cells.
TUNEL Assay
Apoptosis was detected in paraffin-embedded colon samples using the Fluo-
rescein In Situ Cell Death Detection Kit (Roche) according to the manufac-
turer’s instructions. Images were taken with a Nikon E800 upright microscope
using appropriate fluorescence filters.
Analysis of Intestinal Permeability in Mice
To determine in vivo intestinal permeability, mice were starved overnight,
and then FITC-dextran (Sigma #FD4) was administered by oral gavage
(44 mg/100 g body weight). After 4 hr, mice were anesthetized, blood was
collected by cardiac puncture, andmice were sacrificed. Serumwas separated
fromwholebloodusingBDMicrotainerSSTTubes (BD#365968), dilutedwithan
equal volumeofPBS (pH7.4), and100ml ofdilutedserumwasadded toa96-well
microplate. The concentration of FITC in serumwasdeterminedby spectropho-
tofluorometry (BioTek),withanexcitationof 485nmandanemissionwavelength
of 528 nm, using serially diluted FITC-dextran as standard. Tumor permeability
was calculated as described in the Supplemental Information.
Probiotic Treatment
Probiotic mixture VSL#3 (15 mg, Grifols) was dissolved in PBS (200 ml) and
administered daily by oral gavage. Control mice were administered PBS.
Statistical Methods
Data are presented as means ± SEM. Statistical significance was determined
by Student’s t test using GraphPad Prism 4 software. p values less than 0.05
were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2014.02.019.C57BL/6 mice and for administration of the p38a inhibitor PH797804.
Data are means ± SEM (n = 7). *p < 0.05.
8 MAPK antibody at the end of the AOM/DSS protocol. Scale bars, 100 mm for
e indicated antibodies.
3580 (SB, 10 mM), PH797804 (PH, 1 mM) or Birb0796 (Birb, 200 nM) for 4 days,
dies.
rier function to suppress colitis-associated tumor initiation. On the other hand,
ibiting apoptosis of transformed epithelial cells. Tumor cells deficient in p38a
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